Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16868
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAlmatroodi, Saleh A-
dc.contributor.authorMcDonald, Christine F-
dc.contributor.authorDarby, Ian A-
dc.contributor.authorPouniotis, Dodie S-
dc.date2015-08-30-
dc.date.accessioned2017-09-26T05:27:53Z-
dc.date.available2017-09-26T05:27:53Z-
dc.date.issued2016-04-
dc.identifier.citationCancer Microenvironment 2016; 9(1): 1-11en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/16868-
dc.description.abstractLung cancer is one of the most commonly reported cancers, and is known to be associated with a poor prognosis. The function of tumour-associated macrophages (TAMs) in lung cancer patients is multifaceted and the literature shows conflicting roles. (I) To analyze the Th1 and Th2 cytokine levels that contribute to the differentiation of M1 and M2 macrophage populations in the serum of patients with NSCLC versus non-cancer controls; and (II) To characterize the M1 and M2 macrophage populations within TAMs in different subtypes of NSCLC compared to non-tumour tissue. The Th1 and Th2 cytokine levels were analyzed in serum using the Bio-Plex assay. In addition, TAMs subsets from non-tumour and tumour tissues were analyzed using immunohistochemistry (IHC). The level of IL-1β, IL-4, IL-6 and IL-8 was found to be increased in the serum of patients with large cell carcinoma but not in other NSCLC subtypes compared to non-cancer controls. In addition, the expression of CD68 and M2 marker CD163 was found to be increased (P ≤ 0.0001) in all NSCLC subtypes compared to non-tumour tissues. In contrast, the expression of iNOS (M1 marker) was decreased in the tumour tissue of patients with adenocarcinoma (P ≤ 0.01) and squamous carcinoma (P ≤ 0.05) but not in large cell carcinoma compared to non-tumour tissue. The results of this study indicate that NSCLC might have the ability to alter phenotype within the lung tumour areas in the local environment (TAMs) but not in the bloodstream in the systemic environment (serum) except for large cell carcinoma.en_US
dc.subjectLung canceren_US
dc.subjectLung tissueen_US
dc.subjectM1 macrophagesen_US
dc.subjectM2 macrophagesen_US
dc.subjectTumour-associated macrophagesen_US
dc.titleCharacterization of M1/M2 tumour-associated macrophages (TAMs) and Th1/Th2 cytokine profiles in patients with NSCLCen_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleCancer Microenvironmenten_US
dc.identifier.affiliationInstitute for Breathing and Sleep, Austin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationCancer & Tissue Repair Laboratory, School of Medical Sciences, RMIT Universityen_US
dc.identifier.affiliationApplied Medical Sciences College, Qassim University, Buraidah, Saudi Arabiaen_US
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/26319408en_US
dc.identifier.doi10.1007/s12307-015-0174-xen_US
dc.type.contentTexten_US
dc.type.austinJournal Articleen_US
local.name.researcherMcDonald, Christine F
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairetypeJournal Article-
crisitem.author.deptInstitute for Breathing and Sleep-
crisitem.author.deptRespiratory and Sleep Medicine-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

8
checked on Feb 23, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.